Acute hemoDynamic effects of rIociguat in patients with puLmonary hypertension Associated with diasTolic heart failurE (DILATE-1): A randomized, double-blind, placebo-controlled, single-dose study

Abstract

Purpose: Approximately 50% of patients with heart failure have a preserved left ventricular ejection fraction (HFpEF). Concomitant pulmonary hypertension (PH) is a major determinant of mortality in this population and preclinical studies suggest that deficient nitric oxide-soluble guanylate cyclase (sGC)-cGMP signaling underlies impaired cardiac relaxation and endothelial dysfunction in these patients. The Phase IIa DILATE-1 study characterized the hemodynamic effects, safety, and pharmacokinetics (PK) of single doses of riociguat, a novel sGC stimulator, in patients with PH due to diastolic HF.